Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ibrutinib-venetoclax found highly active in hard-to-treat CLL

Key clinical point: The combination of ibrutinib and venetoclax has good antitumor activity in relapsed or refractory CLL.

Major finding: After 12 months of combination therapy, the rate of MRD negativity was 53% for blood and 36% for marrow.

Study details: A single-arm, open-label, phase 2 trial of combination ibrutinib and venetoclax in 53 patients with relapsed or refractory CLL (CLARITY study).

Disclosures: The trial was supported by Bloodwise under the Trials Acceleration Programme, by the National Institute for Health Research Leeds Clinical Research Facility, and by an unrestricted educational grant from Janssen-Cilag and AbbVie. Ibrutinib was provided free of charge by Janssen-Cilag, and venetoclax was provided free of charge by AbbVie. Dr. Hillmen reported financial relationships with Janssen, AbbVie, Roche, Pharmacyclics, and Gilead Sciences.

Citation:

Hillmen P et al. J Clin Oncol. 2019 Jul 11. doi: 10.1200/JCO.19.00894.